TY - JOUR
T1 - Anti-complement activity of the Ixodes scapularis salivary protein Salp20
AU - Hourcade, Dennis E.
AU - Akk, Antonina M.
AU - Mitchell, Lynne M.
AU - Zhou, Hui fang
AU - Hauhart, Richard
AU - Pham, Christine T.N.
N1 - Funding Information:
Research reported in this publication was supported by NIH AI051436 and by the Protein Production and Purification Facility of the Rheumatic Diseases Core center at Washington University School of Medicine (NIH P30AR048335). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We are grateful to Drs. Aravinda M. de Silva and Katharine R. Tyson (University of North Carolina, Chapel Hill) for suggesting the use of Salp20 in the mouse AAA disease models and for generously providing purified recombinant Salp20 (S20NS) and High Five cells stably transfected with the pIB-S20NS expression vector. We also thank Ms. Madonna Bogacki for manuscript assistance. Dennis Hourcade is a consultant for Alexion Pharmaceuticals, Inc.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Complement, a major component of innate immunity, presents a rapid and robust defense of the intravascular space. While regulatory proteins protect host cells from complement attack, when these measures fail, unrestrained complement activation may trigger self-tissue injury, leading to pathologic conditions. Of the three complement activation pathways, the alternative pathway (AP) in particular has been implicated in numerous disease and injury states. Consequently, the AP components represent attractive targets for therapeutic intervention. The common hard-bodied ticks from the family Ixodidae derive nourishment from the blood of their mammalian hosts. During its blood meal the tick is exposed to host immune effectors, including the complement system. In defense, the tick produces salivary proteins that can inhibit host immune functions. The Salp20 salivary protein of Ixodes scapularis inhibits the host AP pathway by binding properdin and dissociating C3bBbP, the active C3 convertase. In these studies we examined Salp20 activity in various complement-mediated pathologies. Our results indicate that Salp20 can inhibit AP-dependent pathogenesis in the mouse. Its efficacy may be part in due to synergic effects it provides with the endogenous AP regulator, factor H. While Salp20 itself would be expected to be highly immunogenic and therefore inappropriate for therapeutic use, its emergence speaks for the potential development of a non-immunogenic Salp20 mimic that replicates its anti-properdin activity.
AB - Complement, a major component of innate immunity, presents a rapid and robust defense of the intravascular space. While regulatory proteins protect host cells from complement attack, when these measures fail, unrestrained complement activation may trigger self-tissue injury, leading to pathologic conditions. Of the three complement activation pathways, the alternative pathway (AP) in particular has been implicated in numerous disease and injury states. Consequently, the AP components represent attractive targets for therapeutic intervention. The common hard-bodied ticks from the family Ixodidae derive nourishment from the blood of their mammalian hosts. During its blood meal the tick is exposed to host immune effectors, including the complement system. In defense, the tick produces salivary proteins that can inhibit host immune functions. The Salp20 salivary protein of Ixodes scapularis inhibits the host AP pathway by binding properdin and dissociating C3bBbP, the active C3 convertase. In these studies we examined Salp20 activity in various complement-mediated pathologies. Our results indicate that Salp20 can inhibit AP-dependent pathogenesis in the mouse. Its efficacy may be part in due to synergic effects it provides with the endogenous AP regulator, factor H. While Salp20 itself would be expected to be highly immunogenic and therefore inappropriate for therapeutic use, its emergence speaks for the potential development of a non-immunogenic Salp20 mimic that replicates its anti-properdin activity.
KW - Complement activation
KW - Complement alternative pathway
KW - Ixodes scapularis
KW - Properdin
KW - Salivary protein
KW - Salp20
UR - http://www.scopus.com/inward/record.url?scp=84949504149&partnerID=8YFLogxK
U2 - 10.1016/j.molimm.2015.11.008
DO - 10.1016/j.molimm.2015.11.008
M3 - Article
C2 - 26675068
AN - SCOPUS:84949504149
SN - 0161-5890
VL - 69
SP - 62
EP - 69
JO - Molecular Immunology
JF - Molecular Immunology
ER -